$0.35 EPS Expected for Elanco Animal Health Incorporated (NYSE:ELAN) This Quarter

Brokerages expect that Elanco Animal Health Incorporated (NYSE:ELANGet Rating) will report $0.35 earnings per share (EPS) for the current quarter, Zacks reports. Five analysts have made estimates for Elanco Animal Health’s earnings. The lowest EPS estimate is $0.34 and the highest is $0.37. Elanco Animal Health reported earnings per share of $0.37 in the same quarter last year, which would suggest a negative year-over-year growth rate of 5.4%. The firm is expected to announce its next earnings report before the market opens on Monday, January 1st.

On average, analysts expect that Elanco Animal Health will report full-year earnings of $1.20 per share for the current fiscal year, with EPS estimates ranging from $1.18 to $1.23. For the next year, analysts forecast that the firm will report earnings of $1.48 per share, with EPS estimates ranging from $1.42 to $1.52. Zacks’ earnings per share averages are an average based on a survey of analysts that cover Elanco Animal Health.

Elanco Animal Health (NYSE:ELANGet Rating) last announced its quarterly earnings results on Thursday, February 24th. The company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.17 by $0.04. The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.10 billion. Elanco Animal Health had a negative net margin of 9.91% and a positive return on equity of 6.59%. Elanco Animal Health’s revenue for the quarter was down 2.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.12 EPS.

A number of brokerages have issued reports on ELAN. Barclays lifted their price target on shares of Elanco Animal Health from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Monday, February 28th. Zacks Investment Research raised shares of Elanco Animal Health from a “sell” rating to a “hold” rating in a research note on Monday, February 28th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $38.43.

NYSE ELAN traded down $0.34 on Friday, reaching $25.31. The company had a trading volume of 2,377,902 shares, compared to its average volume of 3,166,018. The company has a quick ratio of 1.16, a current ratio of 1.99 and a debt-to-equity ratio of 0.80. The stock has a market capitalization of $11.98 billion, a PE ratio of -26.36, a price-to-earnings-growth ratio of 1.09 and a beta of 0.78. The firm’s 50 day moving average price is $26.57 and its 200 day moving average price is $28.21. Elanco Animal Health has a 12 month low of $24.15 and a 12 month high of $37.49.

In other news, Director R David Hoover purchased 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 1st. The stock was purchased at an average cost of $28.66 per share, with a total value of $143,300.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 6.11% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the stock. Dodge & Cox boosted its position in Elanco Animal Health by 510.5% in the 4th quarter. Dodge & Cox now owns 22,218,300 shares of the company’s stock valued at $630,555,000 after buying an additional 18,579,176 shares during the period. Franklin Resources Inc. boosted its position in Elanco Animal Health by 67.3% in the 3rd quarter. Franklin Resources Inc. now owns 11,854,595 shares of the company’s stock valued at $378,043,000 after buying an additional 4,769,153 shares during the period. Sculptor Capital LP purchased a new stake in Elanco Animal Health in the 3rd quarter valued at about $138,752,000. Norges Bank purchased a new stake in Elanco Animal Health in the 4th quarter valued at about $120,639,000. Finally, Rockefeller Capital Management L.P. boosted its position in Elanco Animal Health by 58,874.1% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 2,658,554 shares of the company’s stock valued at $84,779,000 after buying an additional 2,654,046 shares during the period. 97.90% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Company Profile (Get Rating)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Featured Stories

Get a free copy of the Zacks research report on Elanco Animal Health (ELAN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.